Assessing the timing of invasive intervention in NSTE-ACS: insights from a meta-analysis and sequential trial
Wei Yang1, Xiao-Zhen Ge1, Chong-Hui Wang2
1Department of Cardiology, Capital Medical University School of Rehabilitation Medicine, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, Beijing, China.
Insights
Early invasive treatment for non-ST-elevation acute coronary syndromes (NSTE-ACS) does not lower death or heart attack risk. However, it significantly reduces recurrent ischemia, improving patient outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Non-ST-elevation acute coronary syndromes (NSTE-ACS) often warrant invasive treatment to reduce myocardial infarction (MI) risk.
- Optimal timing for invasive interventions in NSTE-ACS remains unclear due to limited understanding of long-term outcomes.
Purpose of the Study:
- To evaluate the impact of early versus delayed invasive intervention timing on clinical outcomes in NSTE-ACS patients.
- To assess the effect of intervention timing on mortality, MI, recurrent ischemia, revascularization, and major bleeding.
Main Methods:
- A meta-analysis incorporating trial sequential analysis (TSA) of 14 randomized controlled trials (RCTs) involving 9,436 NSTE-ACS patients.
- Studies were categorized into early (<24h) and delayed (≥24h) invasive intervention groups based on catheterization timing.
- Primary endpoints included all-cause death or MI; secondary endpoints included recurrent ischemia, revascularization, and major bleeding.
Main Results:
- Early intervention did not significantly decrease all-cause mortality or MI incidence compared to delayed intervention.
- No significant differences were found in revascularization or major bleeding rates between early and delayed intervention groups.
- A significant reduction in recurrent ischemia was observed with early intervention, confirmed by TSA and long-term follow-up.
Conclusions:
- For NSTE-ACS patients, early invasive treatment does not improve survival or reduce MI rates.
- Early invasive intervention is associated with a lower incidence of recurrent ischemia in NSTE-ACS patients.
- The findings support early intervention for reducing recurrent ischemia, though not mortality or MI.
Background:
Invasive approaches are commonly recommended for treating patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) to lower the risk of death caused by myocardial infarction (MI). However, the timing for implementing relevant interventions remains challenging to be determined, largely due to poorly understanding of the long-term clinical outcomes.
Methods:
A meta analysis with trial sequential analysis (TSA) was conducted to evaluate the impact of timing on the outcomes of invasive interventions for NSTE-ACS patients. A comprehensive search of PubMed and EMBASE databases identified 14 randomized controlled trials (RCTs), encompassing 16 studies with a total of 9,436 patients, in which two trials have additional long-term follow-up studies. Based on the timing of catheterization, all studies were categorized into two groups: early intervention group (median intervention time <24 h; range from 0.5-9.3 h) and delayed intervention group (median intervention time ≥24 h; range from 18.3-86 h). Clinical outcomes were assessed for primary endpoints (all-cause death or MI) and secondary endpoints (recurrent ischemia, requiring cardiac revascularization or major bleeding) respectively.
Results:
Early intervention did not significantly reduce all-cause mortality or the incidence of MI compared with delayed intervention. The frequency of revascularization and major bleeding were also similar between the two groups. A significant reduction was observed for the incidence of recurrent ischemia in early intervention group. Further analyses confirmed those findings across both short-term follow-up (30 days) and mid-to-long-term follow-up (180 days to 5 years). TSA provided additional evidence supporting the protective benefit of early intervention for recurrent ischemia but not for others.
Conclusions:
For patients with NSTE-ACS, early invasive treatment does not reduce all-cause mortality or incidence of MI but is associated with a lower frequency of recurrent ischemia.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Acute Coronary Syndrome V: Nursing Management